Navarro Joaquín, Aristimuño Carol, Sánchez-Ramón Silvia, Vigil Dolores, Martínez-Ginés Ma Luisa, Fernández-Cruz Eduardo, de Andrés Clara
Department of Immunology, Gregorio Marañón University General Hospital, Madrid, Spain.
J Neuroimmunol. 2006 Jul;176(1-2):153-61. doi: 10.1016/j.jneuroim.2006.03.022. Epub 2006 May 15.
Glucocorticoids remain the treatment of choice for MS relapses. However, little is known on the effect of intravenous methylprednisolone (IVMP) on dendritic cells (DCs) and regulatory T-cells (TReg). Our main goal was to quantify circulating myeloid and plasmacytoid DCs (mDCs and pDCs), and TReg at MS relapse versus healthy controls; and to analyse the short-term changes after IVMP for MS relapse. MS patients at relapse compared to controls showed higher %CD4+CD25high+ TReg (p<0.01). After 5-days of IVMP, activated T-lymphocytes (p=0.001), pDCs (p<0.0001), and CD11c+ mDCs (p<0.0001) decreased. By contrast, CD4+CD25+ and CD4+CD25high+ TReg further increased (p<0.0001 both). Changes on these subsets may play a relevant role in the immunosuppressive activity of this drug.
糖皮质激素仍然是治疗多发性硬化症复发的首选药物。然而,关于静脉注射甲基强的松龙(IVMP)对树突状细胞(DCs)和调节性T细胞(TReg)的影响,我们知之甚少。我们的主要目标是量化复发型多发性硬化症患者与健康对照者循环中的髓样和浆细胞样DCs(mDCs和pDCs)以及TReg;并分析IVMP治疗多发性硬化症复发后的短期变化。与对照组相比,复发期的多发性硬化症患者显示出更高比例的CD4 + CD25high + TReg(p < 0.01)。IVMP治疗5天后,活化的T淋巴细胞(p = 0.001)、pDCs(p < 0.0001)和CD11c + mDCs(p < 0.0001)减少。相比之下,CD4 + CD25 + 和CD4 + CD25high + TReg进一步增加(两者均p < 0.0001)。这些亚群的变化可能在该药物的免疫抑制活性中发挥相关作用。